Tiago Emanuel M Costa1, Julia C Lauar1, Mariana L R Innecchi1, Venceslau A Coelho2, Rosa M A Moysés1, Rosilene M Elias3,4. 1. Division of Nephrology, Department of Medicine, Hospital das Clinicas HCFMUSP, Sao Paulo, (SP), Brazil. 2. Division of Geriatrics, Department of Medicine, Hospital das Clinicas HCFMUSP, Sao Paulo, (SP), Brazil. 3. Division of Nephrology, Department of Medicine, Hospital das Clinicas HCFMUSP, Sao Paulo, (SP), Brazil. rosilenemotta@hotmail.com. 4. Universidade Nove de Julho (UNINOVE), Sao Paulo, (SP), Brazil. rosilenemotta@hotmail.com.
Abstract
PURPOSE: Hyperuricemia is common among patients with chronic kidney disease (CKD). In the general population, hyperuricemia is associated with secondary hyperparathyroidism (SHPT), in a mechanism that involves vitamin D metabolism. Data for patients with CKD, however, are scarce. We aimed to evaluate the relationship between hyperuricemia and mineral and bone metabolism, particularly hyperparathyroidism. METHODS: This is a retrospective study that included 922 adult patients with stages 3, 4, or 5 CKD, not on dialysis. Clinical, demographic, and biochemical data were collected from charts and included uric acid, parathyroid hormone (PTH), 25(OH)-vitamin D, calcium, phosphate, renal function (estimated glomerular filtration rate-eGFR), and medications such as allopurinol, furosemide, and cholecalciferol. SHPT was defined as PTH > 65 pg/ml. RESULTS: Our patients were mostly Caucasian women, with a mean age of 64 ± 16 years. SHPT and hyperuricemia were observed in 70% and 62.4% of patients, respectively. Patients with SHPT presented higher levels of uric acid (7.2 ± 1.8 vs. 6.6 ± 1.7 mg/dL, p = 0.0001) and a higher frequency of hyperuricemia (66% vs. 33%, p = 0.0001). Patients with hyperuricemia were mostly female, with lower eGFR, higher phosphate, and higher PTH. The risk of hypovitaminosis D was higher among patients with SHPT (69.7% vs. 53.1%, p = 0.0001). Hyperuricemia remained independently associated with hyperparathyroidism, (p = 0.033) even after adjustments for eGFR, calcium, phosphate, hypovitaminosis D, and use of allopurinol, calcitriol, furosemide, and cholecalciferol. CONCLUSION: Hyperuricemia seems to be a contributing factor for SHPT in patients with CKD. The mechanisms behind this finding have yet to be elucidated.
PURPOSE: Hyperuricemia is common among patients with chronic kidney disease (CKD). In the general population, hyperuricemia is associated with secondary hyperparathyroidism (SHPT), in a mechanism that involves vitamin D metabolism. Data for patients with CKD, however, are scarce. We aimed to evaluate the relationship between hyperuricemia and mineral and bone metabolism, particularly hyperparathyroidism. METHODS: This is a retrospective study that included 922 adult patients with stages 3, 4, or 5 CKD, not on dialysis. Clinical, demographic, and biochemical data were collected from charts and included uric acid, parathyroid hormone (PTH), 25(OH)-vitamin D, calcium, phosphate, renal function (estimated glomerular filtration rate-eGFR), and medications such as allopurinol, furosemide, and cholecalciferol. SHPT was defined as PTH > 65 pg/ml. RESULTS: Our patients were mostly Caucasian women, with a mean age of 64 ± 16 years. SHPT and hyperuricemia were observed in 70% and 62.4% of patients, respectively. Patients with SHPT presented higher levels of uric acid (7.2 ± 1.8 vs. 6.6 ± 1.7 mg/dL, p = 0.0001) and a higher frequency of hyperuricemia (66% vs. 33%, p = 0.0001). Patients with hyperuricemia were mostly female, with lower eGFR, higher phosphate, and higher PTH. The risk of hypovitaminosis D was higher among patients with SHPT (69.7% vs. 53.1%, p = 0.0001). Hyperuricemia remained independently associated with hyperparathyroidism, (p = 0.033) even after adjustments for eGFR, calcium, phosphate, hypovitaminosis D, and use of allopurinol, calcitriol, furosemide, and cholecalciferol. CONCLUSION: Hyperuricemia seems to be a contributing factor for SHPT in patients with CKD. The mechanisms behind this finding have yet to be elucidated.
Authors: AbdelAal Mohammed; Mohamed A Marie; Dina O Abdulazim; Mohammed Hassan; Olfat Shaker; Ghada Ayeldeen; Mona M Salem; Usama A Sharaf El Din Journal: Nephron Date: 2020-12-30 Impact factor: 2.847
Authors: Alessandro Doria; Andrzej T Galecki; Cathie Spino; Rodica Pop-Busui; David Z Cherney; Ildiko Lingvay; Afshin Parsa; Peter Rossing; Ronald J Sigal; Maryam Afkarian; Ronnie Aronson; M Luiza Caramori; Jill P Crandall; Ian H de Boer; Thomas G Elliott; Allison B Goldfine; J Sonya Haw; Irl B Hirsch; Amy B Karger; David M Maahs; Janet B McGill; Mark E Molitch; Bruce A Perkins; Sarit Polsky; Marlon Pragnell; William N Robiner; Sylvia E Rosas; Peter Senior; Katherine R Tuttle; Guillermo E Umpierrez; Amisha Wallia; Ruth S Weinstock; Chunyi Wu; Michael Mauer Journal: N Engl J Med Date: 2020-06-25 Impact factor: 91.245
Authors: Sunil V Badve; Elaine M Pascoe; Anushree Tiku; Neil Boudville; Fiona G Brown; Alan Cass; Philip Clarke; Nicola Dalbeth; Richard O Day; Janak R de Zoysa; Bettina Douglas; Randall Faull; David C Harris; Carmel M Hawley; Graham R D Jones; John Kanellis; Suetonia C Palmer; Vlado Perkovic; Gopala K Rangan; Donna Reidlinger; Laura Robison; Robert J Walker; Giles Walters; David W Johnson Journal: N Engl J Med Date: 2020-06-25 Impact factor: 91.245
Authors: Emily S Andrews; Loni Perrenoud; Kristen L Nowak; Zhiying You; Andreas Pasch; Michel Chonchol; Jessica Kendrick; Diana Jalal Journal: PLoS One Date: 2018-10-24 Impact factor: 3.240